

September 10, 2015



Award Winning Cancer Researcher, Dr. Bruce R. Zetter, Joins MetaStat, Inc. Scientific and Clinical Advisory Board

BOSTON, MA -- (Marketwired) -- 09/10/15 -- MetaStat, Inc. (OTCQB: MTST), a molecular diagnostics company focused on developing and commercializing tissue-based diagnostic tests for prediction of cancer metastasis, announced today Bruce R. Zetter, PhD has joined the company's Scientific and Clinical Advisory Board. Dr. Zetter is the Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School. He is an internationally recognized leader in cancer research, tumor progression, cancer diagnosis, cancer metastasis, and tumor angiogenesis.

"We are truly thrilled to have Bruce join our team of advisors," said Douglas A. Hamilton, President and Chief Executive Officer of MetaStat. "Through his groundbreaking research, Dr. Zetter's contribution to the fight against cancer is truly profound and the experience he brings to MetaStat is invaluable as we intend to expand the breadth and depth of our core diagnostic platform and future product offerings."

Dr. Zetter conducts research at Children's Hospital, Boston where he has served as Vice President of Research and Chief Scientific Officer and is on the faculty of Harvard Medical School since 1978. At Children's Hospital, Dr. Zetter and Dr. Judah Folkman demonstrated that endothelial cells in large blood vessels are distinct from those in capillaries, a cornerstone observation in the field of angiogenesis. Dr. Zetter went on to discover the world's first angiogenesis inhibitor, interferon-alpha.

Dr. Zetter has won numerous national and international awards for his work in the field of cancer research, including a Faculty Research Award from the American Cancer Society, a Creativity Award from the Prostate Cancer Foundation and two MERIT awards from the US National Cancer Institute. He has published more than 150 research papers and has served on the editorial boards of 11 peer-reviewed journals. He has also received three teaching awards from the students at Harvard Medical School for excellence as a teacher and as a course director. A frequent lecturer, Dr. Zetter has given over 300 lectures to universities, conferences and businesses and has served as an expert witness for the United States Senate Cancer Coalition hearings in Washington. In November 2015, Dr. Zetter will Co-Chair the [American Association of Clinical Research's Special Conference on Tumor Metastasis](#).

Prior to his work at Harvard, Dr. Zetter received a B.A. degree in Anthropology from Brandeis University and a Ph.D. from the University of Rhode Island. Dr. Zetter completed fellowships at MIT, the Salk Institute, and the University of California, San Francisco.

About MetaStat, Inc.

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes tissue-based diagnostic tests for early and reliable prediction of cancer metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the Mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite *Breast*[™] and MenaCalc[™] assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat's testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston, MA.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investors:

MetaStat, Inc.

Rick Pierce, 617-531-0874

Rpierce@metastat.com

Source: MetaStat, Inc.